The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US

被引：0
|
作者：
Buthainah Ghanem
Lu Shi
机构：
[1] Chapman University,Department of Pharmaceutical Economics and Policy, School of Pharmacy
[2] Oregon State University,College of Public Health and Human Sciences
来源：
BioDrugs | 2022年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：773 / 780
页数：7
相关论文
共 50 条
  • [21] Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
    Connarn, Jamie N.
    Witjes, Han
    van Zutphen-van Geffen, Marielle
    de Greef, Rik
    Campbell, Timothy B.
    Hege, Kristen
    Zhou, Simon
    Lamba, Manisha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1687 - 1697
  • [22] Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma (vol 37, pg 1779, 2021)
    Martin, Tom
    Usmani, Saad Z.
    Schecter, Jordan M.
    Vogel, Martin
    Jackson, Carolyn C.
    Deraedt, William
    Tian, Hong
    Yeh, Tzu-min
    Banerjee, Arnob
    Pacaud, Lida
    Garrett, Ashraf
    Haltner, Anja
    Cameron, Chris
    Van Sanden, Suzy
    Diels, Joris
    Valluri, Satish
    Samjoo, Imtiaz A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (12) : 2197 - 2208
  • [23] Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
    Bar, Noffar
    Diels, Joris
    van Sanden, Suzy
    Mendes, Joao
    Hernando, Teresa
    Cost, Patricia
    Schecter, Jordan M.
    Lendvai, Nikoletta
    Patel, Nitin
    Ishida, Tadao
    Jeremy, E. R.
    Harrison, Simon J.
    Lopez-Munoz, Nieves
    BLOOD, 2023, 142
  • [24] Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
    Sidana, Surbhi
    Peres, Lauren C.
    Hashmi, Hamza
    Hosoya, Hitomi
    Ferreri, Christopher
    Khouri, Jack
    Dima, Danai
    Atrash, Shebli
    Voorhees, Peter
    Simmons, Gary
    Sborov, Douglas W.
    Kalariya, Nilesh
    Hovanky, Vanna
    Bharadwaj, Sushma
    Miklos, David
    Wagner, Charlotte
    Kocoglu, Mehmet H.
    Kaur, Gurbakhash
    Davis, James A.
    Midha, Shonali
    Janakiram, Murali
    Freeman, Ciara
    Alsina, Melissa
    Locke, Frederick
    Gonzalez, Rebecca
    Lin, Yi
    Mcguirk, Joseph
    Afrough, Aimaz
    Shune, Leyla
    Patel, Krina K.
    Hansen, Doris K.
    HAEMATOLOGICA, 2024, 109 (03) : 777 - 786
  • [25] Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
    McGarvey, November
    Ung, Brian
    Carattini, Thomas
    Imanak, Ken
    Lee, Abraham
    Campbell, Timothy B.
    Patwardhan, Pallavi
    ADVANCES IN THERAPY, 2023, 40 (10) : 4626 - 4638
  • [26] Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
    November McGarvey
    Brian Ung
    Thomas Carattini
    Ken Imanak
    Abraham Lee
    Timothy B. Campbell
    Pallavi Patwardhan
    Advances in Therapy, 2023, 40 : 4626 - 4638
  • [27] Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
    Hosoya, Hitomi
    Fernandez-Pol, Sebastian
    Gubatan, John
    Ehlinger, Zachary
    Lohman, Claire
    Torres, Armando N. Bastidas
    Najidh, Safa
    Kwang, Alexa
    Duran, George
    Wright, Charles
    Kennedy, Vanessa E.
    Bharadwaj, Sushma
    Smith, Melody
    Dahiya, Saurabh
    Frank, Matthew J.
    Muffly, Lori
    Weng, Wen-Kai
    Sahaf, Bita
    Kurtz, David
    Mackall, Crystal L.
    Khodadoust, Michael S.
    Miklos, David B.
    Sidana, Surbhi
    Mikkilineni, Lekha
    BLOOD, 2024, 144 : 4846 - 4847
  • [28] Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
    Hari, Parameswaran
    Berdeja, Jesus G.
    De Stefano, Valerio
    Gay, Francesca
    Hooper, Becky
    Haltner, Anja
    Kumar, Shaji
    Martin, Thomas
    Mateos, Maria-Victoria
    Moreau, Philippe
    Rosta, Emily
    Samjoo, Imtiaz A.
    Usmani, Saad Z.
    Weisel, Katja
    Jackson, Carolyn C.
    Olyslager, Yunsi
    Schecter, Jordan M.
    Vogel, Martin
    Garrett, Ashraf
    Lee, Sam
    Nesheiwat, Tonia
    Pacaud, Lida
    Zhou, Changwei
    Valluri, Satish
    Costa, Luciano J.
    Lin, Yi
    BLOOD, 2021, 138
  • [29] MINIMAL RESIDUAL DISEASE NEGATIVITY AS A MEASURE OF RESPONSE TO CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Aronson, Elizabeth
    Madduri, Deepu
    Suarez, Jacklyn
    Florendo, Erika
    Pacaud, Lida
    Steinbach, Mary
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [30] Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
    Trando, Aaron
    Ghamsari, Farid
    Yeung, Philip
    Costello, Caitlin
    Saunders, Ila
    Jeong, Ah-Reum
    BIOMEDICINES, 2025, 13 (01)
12345